FDA Outlines Steps For Changing Drug Safety Controls
Law360, New York (April 6, 2015, 2:32 PM EDT) -- The U.S. Food and Drug Administration on Monday explained how changes to the so-called risk evaluation and mitigation strategies of prescription drugs should be reported, its latest effort to clarify muddled policies on warnings and restrictions for higher-risk products.
The FDA's action came in guidance that was prompted by the 2012 user fee law, which included provisions aimed at streamlining changes to REMS — risk-management plans that warn of serious side effects and restrict how drugs are distributed, prescribed or dispensed. Changes are common, and in fact, the FDA has lifted about two-thirds of the 200 REMS that it initially required....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!